Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
Tazocin 2 g / 0.25 g powder for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for solution for infusion. White to off-white powder. |
Each vial contains piperacillin (as sodium salt) equivalent to 2 g and tazobactam (as sodium salt) equivalent to 0.25 g.
Excipient with known effect: Each vial of Tazocin 2 g / 0.25 g contains 130 mg of sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Piperacillin |
Piperacillin is a broad-spectrum, semisynthetic penicillin. Piperacillin exerts bactericidal activity by inhibition of both septum and cell-wall synthesis. |
|
| Tazobactam |
Tazobactam is a beta-lactam structurally related to penicillins. It is an inhibitor of many molecular Class A beta-lactamases, including CTX-M, SHV, and TEM enzymes. |
| List of Excipients |
|---|
|
Edetate disodium (EDTA) |
30 ml Type I glass vial with a bromo-butyl rubber stopper and flip-off seal.
Pack sizes: 1, 5, 10, 12, 25 or 50 vials per carton.
Not all pack sizes may be marketed.
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
PL 00057/1293
19/09/2011
| Drug | Countries | |
|---|---|---|
| TAZOCIN | Brazil, Cyprus, Ecuador, Estonia, Hong Kong, Lithuania, Malta, Mexico, New Zealand, Poland, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
